Caisse DE Depot ET Placement DU Quebec Acquires 94,923 Shares of DexCom, Inc. (NASDAQ:DXCM)

Caisse DE Depot ET Placement DU Quebec raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 235.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 135,323 shares of the medical device company's stock after purchasing an additional 94,923 shares during the period. Caisse DE Depot ET Placement DU Quebec's holdings in DexCom were worth $9,072,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of DXCM. Jennison Associates LLC increased its stake in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock valued at $464,782,000 after acquiring an additional 6,544,102 shares during the period. Legal & General Group Plc increased its stake in DexCom by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock worth $339,352,000 after purchasing an additional 49,076 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after buying an additional 876,739 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company's stock worth $183,298,000 after buying an additional 288,381 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in shares of DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock worth $276,538,000 after acquiring an additional 353,019 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on DXCM shares. Wells Fargo & Company increased their target price on DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, October 25th. Stifel Nicolaus boosted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a report on Friday, August 23rd. Sanford C. Bernstein increased their price objective on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Robert W. Baird upped their target price on DexCom from $80.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, August 5th. Finally, Piper Sandler reiterated an "overweight" rating and set a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Trading Up 2.0 %

Shares of DXCM traded up $1.60 during trading hours on Tuesday, hitting $80.91. 3,551,800 shares of the stock traded hands, compared to its average volume of 3,917,172. The firm has a market capitalization of $31.60 billion, a PE ratio of 48.45, a price-to-earnings-growth ratio of 2.43 and a beta of 1.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business has a fifty day moving average of $71.83 and a 200-day moving average of $86.83.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,431 shares of company stock worth $399,319. Insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.